Complete financial analysis of Excelsior Biopharma Inc. (6496.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Excelsior Biopharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Frontline Corporation Limited (FRONTCORP.BO) Income Statement Analysis – Financial Results
- Cogeco Communications Inc. (CGEAF) Income Statement Analysis – Financial Results
- Biotron Limited (BIT.AX) Income Statement Analysis – Financial Results
- STO Express Co., Ltd. (002468.SZ) Income Statement Analysis – Financial Results
- Orford Mining Corporation (ORMFF) Income Statement Analysis – Financial Results
Excelsior Biopharma Inc. (6496.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.excelsiorgroup.com.tw
About Excelsior Biopharma Inc.
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases. It also offers test kits under the Actim name to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking. In addition, the company provides toothpaste, and mouth wash and gel products under the Oral7 name; and food and medical beauty maintenance products. Further, it imports and exports active pharmaceutical ingredients; and engages in the research of technologies, and pharmaceutical technologies transfer and cooperative development and improvement activities. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was incorporated in 1988 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 771.56M | 671.76M | 1.34B | 1.44B | 1.54B |
| Cost of Revenue | 464.63M | 384.59M | 1.05B | 1.13B | 1.19B |
| Gross Profit | 306.93M | 287.17M | 293.35M | 310.11M | 353.59M |
| Gross Profit Ratio | 39.78% | 42.75% | 21.92% | 21.48% | 22.96% |
| Research & Development | 62.51M | 42.32M | 56.00M | 57.31M | 50.54M |
| General & Administrative | 124.60M | 105.34M | 101.05M | 93.10M | 95.02M |
| Selling & Marketing | 199.97M | 172.48M | 140.61M | 118.86M | 122.22M |
| SG&A | 324.57M | 277.82M | 241.65M | 211.96M | 216.26M |
| Other Expenses | 0.00 | 3.48M | 2.87M | 5.51M | 0.00 |
| Operating Expenses | 388.06M | 320.13M | 297.65M | 269.27M | 266.81M |
| Cost & Expenses | 852.69M | 704.72M | 1.34B | 1.40B | 1.45B |
| Interest Income | 5.24M | 4.17M | 406.00K | 429.00K | 854.00K |
| Interest Expense | 6.37M | 4.35M | 4.54M | 2.12M | 1.24M |
| Depreciation & Amortization | 46.22M | 26.06M | 28.65M | 27.37M | 18.53M |
| EBITDA | -29.37M | 4.41M | 23.16M | 74.15M | 105.31M |
| EBITDA Ratio | -3.81% | 0.11% | 2.06% | 5.14% | 6.84% |
| Operating Income | -81.13M | -25.32M | -1.02M | 46.78M | 86.78M |
| Operating Income Ratio | -10.51% | -3.77% | -0.08% | 3.24% | 5.63% |
| Total Other Income/Expenses | -823.00K | 3.30M | -1.26M | 3.82M | 5.04M |
| Income Before Tax | -81.95M | -25.99M | -10.03M | 45.30M | 91.82M |
| Income Before Tax Ratio | -10.62% | -3.87% | -0.75% | 3.14% | 5.96% |
| Income Tax Expense | 9.06M | 7.76M | 5.62M | 10.00M | 20.81M |
| Net Income | -91.01M | -33.76M | -15.65M | 35.30M | 71.01M |
| Net Income Ratio | -11.80% | -5.03% | -1.17% | 2.45% | 4.61% |
| EPS | -1.94 | -0.72 | -0.34 | 0.76 | 1.52 |
| EPS Diluted | -1.98 | -0.71 | -0.34 | 0.73 | 1.52 |
| Weighted Avg Shares Out | 46.91M | 46.67M | 46.51M | 46.67M | 46.72M |
| Weighted Avg Shares Out (Dil) | 45.92M | 47.51M | 46.51M | 49.25M | 46.85M |
Source: https://incomestatements.info
Category: Stock Reports